Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewVU 0360172 hydrochloride is a positive allosteric modulator of mGlu5 receptors (EC50 = 16 nM; Ki = 195 nM). Selective for mGlu5; displays no significant activity at mGlu1, mGlu2 or mGlu4 receptors. Exhibits antipsychotic-like activity in a rodent model. Also reduces spontaneous spike and wave discharges without affecting motor behaviour in a rat model of absence epilepsy.
VU 0360172 hydrochloride is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 330.78 |
Formula | C18H15FN2O.HCl |
Storage | Store at +4°C |
Purity | ≥98% (HPLC) |
CAS Number | 1309976-62-2 |
PubChem ID | 53384852 |
InChI Key | NBGAPTWZQXSEAA-UHFFFAOYSA-N |
Smiles | FC1=CC=CC(C#CC2=CC=C(C(NC3CCC3)=O)C=N2)=C1.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 16.54 | 50 | |
ethanol | 8.27 | 25 |
The following data is based on the product molecular weight 330.78. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.5 mM | 6.05 mL | 30.23 mL | 60.46 mL |
2.5 mM | 1.21 mL | 6.05 mL | 12.09 mL |
5 mM | 0.6 mL | 3.02 mL | 6.05 mL |
25 mM | 0.12 mL | 0.6 mL | 1.21 mL |
References are publications that support the biological activity of the product.
Rodriguez et al (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol.Pharmacol. 78 1105 PMID: 20923853
D'Amore et al (2013) Potentiation of mGlu5 receptors with the novel enhancer, VU0360172, reduces spontaneous absence seizures in WAG/Rij rats. Neuropharmacology 66 330 PMID: 22705340
If you know of a relevant reference for VU 0360172 hydrochloride, please let us know.
View all Glutamate (Metabotropic) Group I Receptor Modulators
Keywords: VU 0360172 hydrochloride, VU 0360172 hydrochloride supplier, VU0360172, hydrochloride, Positive, allosteric, modulators, mGlu5, mGluR5, mGlur, Group, I, Receptors, Glutamate, Metabotropic, antipsychotic, absence, epilepsy, PAM, (Metabotropic), 4323, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for VU 0360172 hydrochloride include:
Hanak et al (2019) Positive modulation of mGluR5 attenuates seizures and reduces TNF-α+ macrophages and microglia in the brain in a murine model of virus-induced temporal lobe epilepsy. Exp.Neurol. 311 194 PMID: 30316834
Bogdan A et al (2021) Enhanced Akt/GSK-3β/CREB signaling mediates the anti-inflammatory actions of mGluR5 positive allosteric modulators in microglia and following traumatic brain injury in male mice. J Neurochem 156 225-248 PMID: 31926033
Do you know of a great paper that uses VU 0360172 hydrochloride from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review VU 0360172 hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.